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 32 
ABSTRACT 33 
Primary rat liver sinusoidal endothelial cells (LSEC) are difficult to maintain in a differentiated 34 
state in culture for scientific studies or technological applications.  Relatively little is known 35 
about molecular regulatory processes that affect LSEC differentiation because of this inability to 36 
maintain cellular viability and proper phenotypic characteristics for extended times in vitro, as 37 
LSEC typically undergo death and detachment around 48-72 hours even when treated with 38 
VEGF.  We demonstrate that particular lipid supplements added to serum-free, VEGF-containing 39 
medium increase primary rat liver LSEC viability and maintain differentiation.  Addition of a 40 
defined lipid combination, or even oleic acid (OA) alone, promotes LSEC survival beyond 72 41 
hours and proliferation to confluency.  Moreover, assessment of LSEC cultures for endocytic 42 
function, CD32b surface expression, and exhibition of fenestrae showed that these differentiation 43 
characteristics were maintained when lipids were included in the medium.  With respect to the 44 
underlying regulatory pathways, we found lipid supplement-enhanced PI3K and MAPK 45 
signaling to be critical for ensuring LSEC function in a temporally-dependent manner.  Inhibition 46 
of Akt activity before 72 hours prevents growth of SECs, whereas MEK inhibition past 72 hours 47 
prevents survival and proliferation.  Our findings indicate that OA and lipids modulate Akt/PKB 48 
signaling early in culture to mediate survival, followed by a switch to a dependence on ERK 49 
signaling pathways to maintain viability and induce proliferation after 72 hours.  We conclude 50 
that free fatty acids can support maintenance of liver LSEC cultures in vitro; key regulatory 51 
pathways involved include early Akt signaling followed by ERK signaling. 52 
Keywords: unsaturated fatty acids, fenestrae, VEGF, CD32b, monoculture 53 
 54 
55 
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INTRODUCTION 56 
Liver sinusoidal endothelial cells (LSEC) play important roles in regulating liver function. LSEC 57 
line capillaries of the microvasculature and possess fenestrae to facilitate filtration between the 58 
liver parenchyma and sinusoid by serving as a selectively permeable barrier (7, 23).  This role is 59 
augmented by high endocytic uptake rates, making LSEC effective scavengers for molecules 60 
such albumin, acetylated low density lipoproteins, hyaluronan and antigens in the bloodstream 61 
(22, 23, 26, 34, 40, 43).  Furthermore, LSEC have a phenotype unique from traditional vascular 62 
endothelial cells, such as pan-endothelial marker CD31 localized only to endosomes in 63 
differentiated, unstimulated LSEC (18).  Differentiated LSEC are capable of affecting resident 64 
liver cell proliferation, survival, or maintaining their quiescence.  As such, loss of function may 65 
underlie various hepatic pathologies (7, 16, 24, 33, 50, 57).   66 
 67 
LSEC are also targets or facilitators of infection and toxicological damage to liver (5).  In 68 
addition to intrinsically vital contributions they make to proper liver tissue function in vivo, 69 
cultured LSEC are important to consider as essential non-parenchymal components of ex vivo 70 
tissue engineered models of liver physiology, which are of emerging importance in drug 71 
discovery and development (19, 29, 47, 51). 72 
 73 
Despite this importance, much of LSEC biology remains unknown because they are difficult to 74 
maintain in a differentiated state for prolonged periods in vitro.  Conventional endothelial 75 
culturing techniques are not as successful with LSEC; low serum concentrations (5%) can be 76 
toxic and cells die within 48 to 72 hours in serum-free monocultures even in the presence of 77 
VEGF (21, 31).  Previously, attempts at serum-free LSEC culture resulted in cell viability 78 
maintenance from 6 up to 30 days with surviving cells maintaining endocytic uptake (20, 21, 31).    79 
Receptor mediated endocytic uptake is a characteristic feature of endothelial phenotype, but is 80 
insufficient for specific characterization of LSEC differentiation as large venule endothelial cells 81 
in the liver, as well as several vascular endothelial cells also exhibit this function (21, 28, 40, 41, 82 
54).  Another rat study was also able to prolong cell survival in vitro with use of multiple growth 83 
factors such as FGF, hepatocyte growth factor, and PMA within the context of hepatocyte-84 
conditioned medium (31). Human LSEC cultures have been reported to be sustained for long 85 
periods, however, these LSEC were positively selected for, or had a higher expression of CD31, 86 
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a marker of LSEC dedifferentiation (14, 32). There are also controversies regarding phenotyping 87 
human LSEC, as there are reports of heterogeneous expression of surface markers used to 88 
characterize LSEC, such as von Willebrand Factor and immunological markers (21). 89 
 90 
This study tested the hypothesis that an alternative approach emphasizing non-protein 91 
components could be beneficial in maintaining LSEC function in culture. Due to the location of 92 
the liver downstream of the intestinal tract and a center for lipid metabolism (10), we 93 
hypothesized that LSEC require lipids to maintain cell viability.  We found that even in serum-94 
free, minimal growth factor (i.e., solely VEGF) media, free fatty acids (FFAs) were able to 95 
sustain LSEC culture.  The addition of lipid supplements to serum-free media with 50 ng/mL 96 
VEGF allowed us to bypass the critical time point between 48 and 72 hours when most 97 
differentiated LSEC die in vitro.  We identified oleic acid (OA) as a major contributing agent 98 
responsible for enhancing this survival. OA and lipids in culture could also eventually induce 99 
proliferation of cells with LSEC phenotype to confluency, although OA alone was insufficient 100 
for maintaining long-term confluent cultures.  Furthermore, our results indicate that OA and 101 
lipids can maintain multiple LSEC phenotype markers simultaneously for at least 5 days in 102 
culture.  Our findings indicate that OA and lipids influence early Akt/PKB signaling to mediate 103 
cell survival, while late ERK signaling is necessary in culture for viability and proliferation to 104 
persist. 105 
106 
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MATERIALS AND METHODS 107 
Chemically Defined Culture Media 108 
Serum/growth factor-free base medium was made as described with modifications (27, 31).  Low 109 
glucose DMEM (Invitrogen, Carlsbad, CA) was supplemented with 0.03g/L L-proline, 0.10g/L 110 
L-ornithine, 0.305 g/L niacinamide, 1 g/L glucose, 2 g/L galactose, 2 g/L BSA, 50 μg/mL 111 
gentamicin  (Sigma-Aldrich, St. Louis, MO), 1 mM L-glutamine (Invitrogen), 5 μg/mL insulin-5 112 
μg/mL transferrin-5 ng/mL sodium selenite (Roche Applied Science, Mannheim, Germany).  113 
“Modified hepatocyte growth medium” (HGM) included 200 μM ethanolamine and 114 
phosphoethanolamine, 100 nM ascorbic acid, 110 nM hydrocortisone (Sigma-Aldrich), 20 115 
μg/mL heparin (Celsus Laboratories, Cincinnati, OH) and 50 ng/mL VEGF (R&D Systems, 116 
Minneapolis, MN).  Additional treatments included 1% Chemically Defined Lipid Concentrate 117 
(~8μM final concentration) (Invitrogen 11905031) or 50 μM OA, FFA-free BSA, 118 
phosphatidylcholine (PC, 50 μM), and lysophosphatidylcholine (LPC 50 μM) (Sigma-Aldrich).  119 
For signaling studies, PI3K inhibitor LY294002 and MEK1/2 inhibitor PD0325901 (EMD 120 
Calbiochem, Gibbstown, NJ) were added to LSEC cultures 4 hours following seeding and 121 
maintained throughout the experiment.  Inhibitors were reconstituted in DMSO (Sigma-Aldrich) 122 
to 20 mM. LY294002 was dosed at concentrations of 10 μM and 3 μM, while PD0325901 was 123 
used at 1 μM and 0.3 μM.  Inhibitors were replenished once a day with fresh medium changes. 124 
 125 
LSEC Isolation and Culture 126 
Livers from approximately 180 to 250 gram male Fisher rats (Taconic, Hudson, NY) were used 127 
under the guidelines set forth by Massachusetts Institute of Technology’s Committee on Animal 128 
Care.  Cells were isolated using a two-step collagenase perfusion (27, 47) using Liberase 129 
Blendzyme (Roche Applied Science) in place of collagenase.  The liver was perfused initially at 130 
25 mL/min and reduced down to 15 mL/min flow rates in calcium free 10 mM HEPES (Sigma-131 
Aldrich) buffer followed by 10 mM HEPES buffer with Blendzyme for cell isolation.  The 132 
supernatant cell suspension from the perfusion was used to isolate LSEC at room temperature (6, 133 
27).  Very briefly, supernatant suspensions were spun down at 50 x g for 3 minutes.  Supernatants 134 
were spun at 100 x g for 4 minutes.  Supernatants following the spin were pelleted at 350  x g for 135 
10 minutes and resuspended in 20 mL modified HGM without VEGF.  The suspension was 136 
loaded over 25%/50% Percoll (Sigma-Aldrich)/PBS layers and centrifuged at 900 x g for 20 137 
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minutes.  The interface between the Percoll layers were taken and resuspended with 1:1 modified 138 
HGM without VEGF before being spun down at 950 x g for 12 minutes.  This LSEC enriched 139 
pellet was then resuspended into modified HGM with 25 ng/mL VEGF and 2% FBS 140 
(Hyclone/Thermo Fisher Scientific, South Logan, UT).  Cells were counted using Sytox Orange 141 
exclusion and Hoechst 33342 (Invitrogen) staining on disposable hemacytometers (inCyto, 142 
Seoul, Korea).  LSEC were then seeded onto 10 μg/mL fibronectin (Sigma-Aldrich) coated tissue 143 
culture plates at 400,000 cells/cm2.  Four to six hours following seeding, culture media were 144 
changed with serum-free modified HGM supplemented with VEGF.  Additional conditions 145 
included supplementing 50 μM OA, 50 μM LPC, 50 μM PC, and 1% lipid concentrate to the 146 
culture over the course of 5 days at 37 °C and 5% CO2.  Media for all cultures were changed on a 147 
daily basis for all experiments. 148 
 149 
Live/Dead Assay 150 
LSEC viability was assessed using the Live/Dead Assay kit (Invitrogen L3224).  LSEC were 151 
incubated for 1 hour with 2 μM Calcein AM and 4 μM Ethidium Bromide Homodimer in 152 
modified HGM.  Cultures were washed with warm media prior to imaging. 153 
 154 
Alamar Blue Metabolic Assay 155 
Metabolic activity of LSEC was assessed over the time period of 5 days using Alamar Blue 156 
(Invitrogen) reduction assays.  Positive reference standards were first made by heating base 157 
modified HGM at 125 °C with 10% Alamar Blue until the entire reagent was oxidized and 158 
converted to a bright shade of red.  On the days of analysis, 10% Alamar Blue reagent was 159 
introduced to each well and allowed to incubate at 37 °C, 5% CO2 for 6 hours prior to screening 160 
in a SpectraMax E2 (MDS Analytical Technologies, Sunnyvale, CA) fluorescent plate reader.   161 
Reference standards were included on each plate as positive controls and served as a point of 162 
reference in interpreting results.  Fluorescent measurements were read by exciting the samples at 163 
530 nm and reading the emission wavelengths at 590 nm. Samples were pooled across 3 164 
biological replicates (5 technical replicates) for a total of 15 data points.  All data points were 165 
normalized to blank readings prior to relative comparison to control samples. 166 
 167 
Acetylated-LDL Uptake Assay 168 
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LSEC were grown on Thermanox coverslips (Nalgene Nunc, Rochester, NY) coated with 10 169 
μg/mL fibronectin.  On day 5, SECs were incubated for four hours with 10 μg/mL 1,1’ 170 
dioctadecyl 3,3,3’,3’ tetramethylindo carbocyanine perchlorate labeled acetylated LDL (Di-I-Ac-171 
LDL) (Biomedical Technologies, Inc., Stoughton, MA).  Cells were washed several times with 172 
probe free modified HGM then rinsed with PBS. LSEC were fixed for 30 minutes in 3% 173 
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA), rinsed with PBS, mounted on 174 
glass slides with Fluormount (Sigma-Aldrich), and sealed with nail polish.  Samples were 175 
compared with positive controls using human dermal microvascular endothelial cells 176 
(HDMVEC) (Lonza Inc., Allendale, NJ). 177 
 178 
Immunofluorescence Microscopy 179 
LSEC were cultured for up to 5 days on Thermanox coverslips coated with 10 μg/mL 180 
fibronectin.  Samples were rinsed with PBS and fixed in 3% paraformaldehyde in PBS for 30 181 
minutes.  Following fixation, samples were rinsed three times with PBS and permeabilized with 182 
0.1% Triton X-100 (Sigma-Aldrich) for one hour, excluding samples immunostained for CD31 183 
which were not permeablized so as to evaluate only surface expression.  Following 184 
permeabilization, samples were rinsed three times with 2% BSA in 0.1% Tween-20 in PBS 185 
(PBS-T).  Samples were blocked with 5% goat or donkey serum (Jackson ImmunoResearch, 186 
West Grove, PA) in 2% BSA PBS-T for 1 hour before overnight incubation at 4 °C with primary 187 
antibodies for anti-rat CD32b/SE-1 (IBL America, Inc., Minneapolis, MN) at 1:100, 188 
CD31/PECAM-1 (Chemicon/Millipore, Temecula, CA) at 1:100, and PCNA (Abcam, 189 
Cambridge, MA) at 1:600.  The following day, samples were rinsed 3 times in 2% BSA PBS-T 190 
before a 1 hour incubation step with secondary AlexaFluor 488/555 (Invitrogen) antibodies at 191 
1:250. Coverslips were then rinsed in 2% BSA PBS-T and stained with 1:500 Hoechst.  192 
Following incubation with secondary antibodies, samples were rinsed once in 2% BSA PBS-T 193 
prior to being treated briefly with nuclear Hoechst staining for 1 minute.  Following Hoechst 194 
staining, samples were rinsed twice in normal PBS before being mounted onto glass slides with 195 
Fluormount and sealed with nail polish.  196 
 197 
Scanning Electron Microscopy (SEM) 198 
LSEC were grown on fibronectin-coated Thermanox coverslips.   On days 3-5, LSEC were 199 
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rinsed with PBS and fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences) in PBS for 30 200 
minutes.   Samples were prepared following previously established protocols (27). 201 
 202 
Flow Cytometry 203 
Twenty-four hours before harvesting, 10 μM of 5-ethynyl-2’-deoxyuridine (EdU) (Invitrogen) 204 
was added to all conditions.  Samples were detached with 0.025% Trypsin (Invitrogen) the 205 
following day, quenched with media containing 10% FBS, and immediately spun down at 1,600 206 
rpm for 5 minutes.  Cells were washed in PBS before being fixed in 2% paraformaldehyde in 207 
PBS for 15-30 minutes at room temperature.  LSEC were centrifuged and resuspended in 1% 208 
BSA in PBS and incubated with primary CD32b antibody (1:100) prior to use of the Click-iT 209 
EdU kit, following manufacturer’s instructions.  Samples were analyzed on an Accuri-C6 210 
(Accuri Cytometers, Inc., Ann Arbor, MI) flow cytometer and processed using FlowJo software 211 
(FlowJo, Ashland, OR).  HDMVEC were used as a negative control population. Total and 212 
cellular events were captured with gates created using forward and side scatter data from 213 
HDMVEC populations. Following this, CD32b and EdU gates were designated using the double 214 
negative HDMVEC population.  215 
 216 
Western Blotting 217 
LSEC were harvested on day 5 of culture by incubating with cell lysis buffer (46) for 30 minutes. 218 
Cell lysis buffer consisted of 1% Triton X-100, 50mM β-glycerophosphate, 10 mM sodium 219 
pyrophosphate, 30 mM sodium fluoride (Sigma-Aldrich), 50 mM Tris (Roche Applied Science), 220 
150 mM sodium chloride, 2 mM EGTA, 1 mM DTT, 1 mM PMSF, 1% Protease Inhibitor 221 
Cocktail and 1% Phosphatase Inhibitor Cocktails (Sigma-Aldrich).  Samples were spun down at 222 
12,000 rpm for 12 minutes at 4 °C and supernatants were reserved.  Total protein content of 223 
sample lysates was determined using micro bicinchoninic acid kits (Thermo Fisher Scientific, 224 
Rockford, IL) before being loaded onto the NuPage Novex system (Invitrogen).  Lysates were 225 
loaded with 6X reducing buffer (Boston BioProducts, Worcester, MA) in 4%-12% Bis-Tris gels 226 
(Invitrogen) and transferred to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA).  227 
Membranes were blocked with 5% BSA in PBS-T and incubated with antibodies for β-actin 228 
(1:5000), phosphoERK1/2 (1:5000), ERK1/2 (1:5000), phosphoAkt (1:1000), and Akt (1:5000) 229 
(Cell Signaling Technology, Beverly, MA) overnight at 4 °C.  Membranes washed and then 230 
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incubated for 1 hour with horseradish peroxidase conjugated anti-mouse and anti-rabbit 231 
antibodies (Amersham/GE Healthcare Biosciences, Pittsburgh, PA) at 1:10,000 dilution in PBS-232 
T with 5% blotting grade nonfat dry milk (Bio-Rad).  Membranes were subsequently visualized 233 
using chemiluminescent ECL kits (Amersham/GE Healthcare Biosciences) on a Kodak Image 234 
Station (Perkin Elmer, Waltham, MA). 235 
 236 
 237 
Image and Statistical Analysis 238 
All experiments were repeated a minimum of three times with duplicate or triplicate samples. 239 
Fluorescent images were analyzed using Cell Profiler (Broad Institute, Cambridge, MA) and 240 
ImageJ (NIH, Bethesda, MD). Intact cell body counts from phase contrast were assessed at 100X 241 
magnification. Cells from a camera area of 1360 by 900 μm were counted from three biological 242 
replicates across seven days. Statistical significance was determined using ANOVA and Student’s 243 
t-test (Microsoft Excel).244 
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RESULTS 245 
FFA lipids support cell survival past the first 48 hours in serum free media.  246 
Isolated LSEC were plated and cultured using different lipid supplements of 50 μM OA or 1% 247 
lipid (a cocktail of saturated and unsaturated fatty acids) (Figure 1).  Immunofluorescence 248 
staining of LSEC 24 hours after isolation indicated high purity of LSEC (Figure 5C).  Distinct 249 
morphological changes were observed starting on day 3 in cultures with 50 μM OA or 1% lipid 250 
supplement, compared to control cultures (Figure 1A, B).  Notably, LSEC cultured with 1% lipid 251 
underwent proliferation, and by day 5, the culture was at or near confluency.  Both regular and 252 
FFA-free BSA were evaluated to account for potential variability of BSA-bound lipids.  Medium 253 
supplemented with 50 μM OA yielded similar results as 1% lipid at day 5 in regular BSA.  When 254 
FFA-free BSA was used, cells treated with 50 μM OA died after day 4 of culture (Figure 1C, D), 255 
although this was not observed with regular BSA.  Untreated cells took on a granular appearance 256 
indicating that lipid moiety is a critical component for LSEC viability (Figure 1B, D). Granular 257 
morphology was also observed in LSEC cultured with PC and LPC (data not shown). 258 
 259 
Live/Dead images of LSEC across conditions in both regular and FFA-free BSA were taken 260 
during five days of culture (Figure 2A, B).  Massive cell death observed in the control concur 261 
with previously reported observations of LSEC demise beyond 48 hours in culture.  While all 262 
conditions experienced cell number decline between days 2 and 3, lipid and OA treated cultures 263 
recovered and proliferated in both types of BSA, with statistically significant differences in 264 
population after day 3 compared to control (p<5E-4). (Figure 2C, D).  Phase and live/dead 265 
staining indicate pronounced and distinct morphological changes for surviving LSEC.  Lipid 266 
supplementation maintained LSEC to day 5.  Cells grown with OA in normal BSA were viable 267 
after 4 days after isolation; however, FFA-free BSA did not synergize with OA to maintain cell 268 
viability.  Lipid and OA conditions had persistently higher total live cell percentages compared to 269 
control, PC, and LPC conditions; PC and LPC did not offer any growth advantage for LSEC 270 
relative to control (p>0.24) (Figure 2).  Live/Dead assay confirmed that LSEC with unhealthy 271 
granular appearance were dead and positive for ethidium bromide.  PC and LPC cell cultures did 272 
not survive past day 2 in regular BSA (data not shown). 273 
 274 
FFAs support metabolic and endocytic functionality in LSEC past day 3.   275 
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OA and lipid supplement supported significantly higher Alamar Blue reduction relative to 276 
control, in agreement with live/dead stain results (Figure 3A).  These trends were also observed 277 
in FFA-free BSA cultures (Figure 3B).  Endocytic capacity was measured using Di-I-Ac-LDL 278 
uptake as a functional assay for endothelial phenotype (Figure 3C).  OA and lipid treatments 279 
sustained high endocytic uptake at day 5; cells positive for nuclear Hoechst were also strongly 280 
positive for Di-I-Ac-LDL.  Many cells in the control did not remain after fixation; those that did 281 
remain stained positive for Hoechst but were negative for Di-I-Ac-LDL.  282 
 283 
LSEC phenotype and proliferation are partially maintained with lipids in growth factor-reduced, 284 
serum-free media.  285 
Following cell number reduction at day 3, LSEC phenotype was assessed.  An important LSEC 286 
hallmark is the presence of fenestrae on cell surfaces.  Using scanning electron microscopy we 287 
found both 50 μM OA and 1% lipid treated LSEC expressed numerous fenestrae at days 3-5 of 288 
culture (Figure 4), while control cells did not maintain fenestrae. Only about 5% of all FFA-289 
treated cells expressed fenestrations in sieve plates. A larger percentage (10-15%) expressed 290 
large holes (Figure 4H, I) that are suspected to be sieve plate remnants. When the population was 291 
taken as a whole, porosity was well below the 10% observed for healthy LSEC in vivo (7), 292 
indicating that FFA alone does not maintain fenestrations at normal levels.  293 
 294 
Another characteristic LSEC marker, CD32b, was used to corroborate phenotype.  295 
Immunostained coverslips revealed that cells treated with FFAs maintained CD32b expression at 296 
day 5 (Figure 5A).  Control cells remaining in culture did not have colocalization of CD32b 297 
surface expression with nuclei; CD32b appeared as punctate staining which were most likely 298 
dead cell remnants.  Non-viable adherent cells appeared less frequently in protocols with 299 
multiple rinse steps (e.g., Di-I-Ac-LDL uptake, Figure 3C; co-immunostaining, Figure 5; flow 300 
cytometry, Figure 6B).  Although we stained for CD31, we did not observe CD31 expression on 301 
the cell surfaces of LSEC in FFA-treated conditions or remaining adherent cells in the control 302 
unless samples were permeabilized prior to staining (Figure 5B).  CD32b+ cells comprised a 303 
greater proportion of total cell populations in lipid treated LSEC in flow cytometry compared to 304 
controls (Figure 6C).  The enhanced presence of CD32b+ cells in OA and lipid is consistent with 305 
immunostaining results. CD32b staining was still present on day 5 cultures treated with lipid 306 
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(Figure 5C) and OA (not shown), but signal intensity was diminished compared to LSEC 307 
evaluated on day 1 following isolation. 308 
 309 
Proliferative capabilities were measured using PCNA and EdU (a BrdU analog) incorporation.  310 
OA and lipid treated cells stained positive for both PCNA and CD32b expression at day 5 while 311 
untreated cells did not (Figure 5A).  Most cells were PCNA- in the control; those that were 312 
PCNA+ were CD32b-.   Day 5 cells had higher proportions CD32b+/ EdU+ cells in OA compared 313 
to control (Figure 6A, C).  1% lipid treated LSEC did not have statistically significant 314 
CD32b+/EdU+ populations over the control.  However, this is likely attributed to the culture 315 
achieving confluency by days 4 and 5 relative to the OA condition; we were able to obtain a 316 
greater number of overall and CD32b+ events for 1% lipid samples than with any other 317 
condition.  Even when debris is included we have statistically significant larger populations of 318 
distinct double positive cells following treatment.  Combined with immunostaining observations, 319 
we can state that PCNA observed in untreated conditions most likely stems from contaminating 320 
cell types and/or dedifferentiated LSEC. 321 
 322 
Temporal dependence of LSEC on PI3K and MAPK pathways observed at Days 3 and 5 in FFA-323 
treated cultures. 324 
Akt and ERK1/2 proteins were probed on days 3 and 5 by Western blotting, as significant 325 
phenotypic changes occurred at these times (Figure 7A, B).  Signaling trends observed for Akt 326 
and ERK1/2 were consistent across biological replicates.  Phospho-Akt/Akt ratios decreased 327 
dramatically by day 5 in OA and lipid treated LSEC.  Day 3 total and phospho-ERK1/2 levels 328 
were similar for all conditions but increased by day 5 in OA and lipid treated LSEC.  Phospho-329 
ERK/ERK ratios remained relatively unchanged for ERK2 but increased by day 5 for ERK1, 330 
indicating ERK1 as the primary contributor to overall phospho-ERK/ERK in OA and lipid 331 
cultures.  Despite no observable statistical significance for phospho-protein signals in Western 332 
blots, we found a temporal significance with regard to total signaling proteins present at days 3 333 
and 5 compared to control conditions.  Total Akt was statistically significant at days 3 (p<0.05) 334 
and 5 for OA (p<0.05) and day 5 lipid (p<0.05) conditions, while total ERK1 (p44) was 335 
statistically significant at day 5 (p<0.05) compared to control.  Phospho-Akt levels remained 336 
relatively constant across all conditions and times, while total Akt increased in treated conditions 337 
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compared to control through day 5.   338 
 339 
Inhibition studies were performed using PI3K inhibitor LY294002 and MEK1/2 inhibitor 340 
PD0325901.  Inhibitors did not affect LSEC for the first 24 hours of incubation (Figure 8A, 9A) 341 
despite lower concentrations effectively reducing downstream Akt and ERK1/2 phosphorylation 342 
(Figure 9D).  By day 2, 10 μM PI3K inhibitor had adverse effects despite addition of OA or lipid 343 
(Figure 8B, 9A-C).  Lower PI3K inhibitor concentrations (3 μM) showed similar effects in 344 
unsupplemented medium, but cultures with OA or lipid survived while only the lipid condition 345 
continued to proliferate (Figure 8B, 9B, C).  High MEK1/2 inhibitor concentrations only slightly 346 
affected OA conditions at day 2 by reducing attached cell number, although culture quality 347 
appeared similar to treatments without inhibitor.  Lipid cultures did not appear to be perturbed by 348 
1 μM MEK1/2 inhibitor by day 2.  MEK1/2 inhibition prevented culture survival after day 4 349 
(Figure 8C,D, 9C).  Lower MEK1/2 inhibitor concentration (0.3 μM) did not vary from the high 350 
dose used (p>>0.05 between all MEK1/2 inhibitor conditions at every time point), indicating 351 
LSEC may be more sensitive to changes downstream of MEK1/2 versus PI3K later in culture. 352 
353 
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DISCUSSION 354 
To test our hypothesis on the requirement of lipids to maintain LSEC viability, we evaluated 355 
several different types of lipids in both regular and FFA-free BSA.  FFA-free BSA permitted 356 
individual testing of lipids for effects on LSEC culture, since native albumin exists bound to a 357 
variety of FFAs (4).  By day 5, we observed that LSEC cultured with FFAs maintained metabolic 358 
and endocytic activity, and proliferated to confluency.  The particular form of lipids delivered to 359 
LSEC was important, since membrane lipids PC and LPC did not maintain viability.  PC and 360 
LPC can facilitate cell signaling and stimulate proliferation in many cell types (2, 42), but did not 361 
maintain LSEC in culture.  We observed that OA alone was insufficient for supporting long-term 362 
culture in FFA-free BSA, although OA could recapitulate the lipid supplement effects in regular 363 
BSA.  In comparison, the 1% lipid supplement, a cocktail of saturated and unsaturated FFAs, 364 
was able to support LSEC viability regardless of the BSA used, affirming the necessity for a 365 
variety of FFAs to sustain survival and proliferation. 366 
 367 
A hallmark of LSEC is the presence of fenestrae, which were maintained in both OA and lipid 368 
samples on day 5.  Of the few living cells remaining in the control, none were found to possess 369 
fenestrae, consistent with previous findings that fenestrae disappear within the first 48 hours of 370 
culture (7).  Additional evaluation with CD32b phenotype marker validated findings that 371 
surviving LSEC in lipid or OA maintained differentiation by expressing this marker, one specific 372 
to liver sinusoidal endothelium (37).  Along with CD32b expression, we also looked at the 373 
proliferative capacity of LSEC, since no previous studies have explicitly reported that 374 
differentiated rat LSEC can undergo proliferation.  We successfully demonstrated that 375 
differentiated LSEC undergo proliferation, via nuclear PCNA expression and EdU incorporation, 376 
when treated with FFAs.  Despite maintenance of several phenotypic characteristics in prolonged 377 
cultures, we did observe degradation of some markers.  Although fenestrae arranged in sieve 378 
plates were observed, they were not abundant in OA and lipid treated cultures, and a large 379 
percentage of these LSEC no longer exhibited fenestrae by day 5. Many cells in the FFA-treated 380 
condition processed large transcytotic pores greater that 1 μm in diameter. These may be the 381 
remnants of sieve plates that have degraded  or fenestrae that have fused.  We noticed that 382 
although LSEC still expressed CD32b, the presence was diffuse and overall fluorescent intensity 383 
was lower than for freshly isolated LSEC (Figure 5C).  Other studies have reported sharper 384 
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declines in specific LSEC phenotype markers during culture, mostly associated with the 385 
dedifferentiation process, recently reported to involve Leda-1 (24, 37).  We suspect that lipid-386 
treated LSEC maintain a state of differentiation that allows them to persist and proliferate in 387 
vitro, but do not maintain physiological levels of CD32b antigen or fenestrations.  388 
 389 
In LSEC we observed phospho-Akt/Akt levels decreased in FFA conditions as time progressed, 390 
while the inverse occurred with phospho-ERK/ERK, primarily by ERK1.  From these 391 
observations and inhibitor studies, we believe low threshold levels of phospho-Akt are required 392 
for cell survival between days 2 and 3.  At this point, high concentrations of PI3K inhibitor 393 
LY294002 abolished the beneficial effects that OA and 1% lipid have on LSECs, while lower 394 
concentrations did not affect cultures.  Beyond 3 days, cells in low PI3K inhibitor could 395 
proliferate and recover albeit not to the level seen in uninhibited samples.  Granular morphology 396 
appeared earlier at day 2 (as opposed to day 3 in control samples without inhibitor) in untreated 397 
samples with PI3K inhibitor.  This may indicate that downstream signals of PI3K are closely 398 
associated with cell survival during this time.  Past day 3, MEK1/2 inhibition was fatal to 399 
cultures, as LSEC did not survive or proliferate regardless of the concentration of MEK1/2 400 
inhibitor PD0325901 added to cultures.  Interestingly, OA and lipid-treated cultured LSEC did 401 
not have a significant dependence on MAPK before this time, as 10 μM inhibitor only slightly 402 
affected the number of cells in culture.  At early time points, MEK1/2 inhibition also prevented 403 
LSECs from undergoing increased spreading seen with FFA treatments.  As such, MAPK 404 
signaling may be partially responsible for the morphology change induced by FFAs before day 3, 405 
but required afterward for survival and proliferation.  406 
  407 
While it is understood that ECM, cell-cell contacts (37), and paracrine/autocrine signaling (17) 408 
are absolutely vital to achieve functional LSEC, consideration of the role of lipids is important 409 
given the results of this study.  Effects of FFAs on LSEC can have several implications on liver 410 
pathophysiology.  In general, lipids are crucial for survival for all mammalian cells as energy 411 
substrates, membrane lipid bases, and influencing cell signal processes (3). Concentrations of 412 
FFAs in circulation can vary dramatically depending on the metabolic state, but have been 413 
reported to be anywhere between 10 μM to 1 mM  in human plasma, though generally within the 414 
range of 200 to 600 μM (25, 44, 45). Approximately 150 μM total plasma FFA is taken up in the 415 
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liver, of which about 50 μM is comprised of OA (and is recapitulated in our experimental 416 
conditions) (25, 30). The liver is the primary organ responsible for lipid metabolism as 75% of 417 
the blood that enters into the liver arrives from the intestine which absorbs lipids from the gut or 418 
lipolysis from adipose tissue (10).  Thus, FFAs are likely to have a profound influence on LSEC.  419 
Past studies have shown that polyunsaturated FFAs can protect hepatocytes from superoxide 420 
radicals (49), while bioactive lipids like sphingosine 1-phosphate provide oxidative protection to 421 
LSEC following liver injury (57).  In contrast, studies also argue for the presence of lipids as 422 
precursors to chronic disease, apoptosis, steatosis, and insulin resistance/diabetes (1, 33, 35, 36).  423 
For example, caveolin-1 is important to lipid metabolism during liver regeneration, but may also 424 
implicate a role of pathogenesis in LSEC since it is upregulated in dedifferentiating cells (8, 10, 425 
50).  Moreover, we observed that cocultures of hepatocytes and LSEC induce hepatic cell death 426 
in lipid conditions, suggesting concentrations beneficial to LSECs can be lipotoxic for 427 
hepatocytes (data not shown).  428 
  429 
OA and other unsaturated FFAs have been reported to have numerous effects on metabolically 430 
active cells although the main mechanisms of OA and other FFA incorporation are still not fully 431 
understood.  OA has been found to participate in crosstalk with EGFR and other pathways by 432 
affecting MAPK and PI3K (12, 13, 52, 53, 55, 56).  However, much of the data from previous 433 
studies are contradictory in either stimulating or inhibiting these pathways dependent on the 434 
system being studied.   435 
 436 
Unsaturated FFAs have been found to be able to protect against oxidative stress by reducing lipid 437 
peroxidation and inhibiting the inflammatory pathway NF-κB which can lead to endothelial cell 438 
activation (9, 11, 15, 39). Thus, OA may prevent oxidative stress in LSEC that decreases ERK1/2 439 
activity (38, 48), thereby allowing cells to resume cell survival and proliferation after day 3. This 440 
would be in agreement with the results we observed in increased phospho-ERK1/2 activity. 441 
Furthermore, increased saturated to unsaturated fatty acid levels are strongly correlated with 442 
insulin resistance and decreased glucose production in the liver (33, 36). The introduction of 443 
more unsaturated FA into the system may facilitate insulin signaling and activation of phospho-444 
Akt for cell survival in our early time points. While it is most likely that FFAs indirectly 445 
modulate proteomic responses via metabolic pathways, we observed distinct changes in 446 
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phospho-protein signaling pathways. We could directly influence viability in OA and lipid 447 
treated LSEC by inhibiting PI3K and MAPK pathways, showing a temporal shift in phospho-448 
protein signaling dependence from PI3K to MAPK.  449 
 450 
Our results implicate the underlying importance of FFAs in the basic function of LSEC, as FFA 451 
modulate LSEC phenotype, survival, and proliferation in the absence of serum.  Changes in the 452 
FFA profile due to shifts in systemic or dietary delivery to the liver can potentially result in 453 
LSEC dysfunction, leading to oxidative stress and activation of inflammatory pathways. 454 
Additionally, decreases in unsaturated FFA (and increase in saturated FFA) could lead to steatosis 455 
and insulin resistance.  As such, lipid balance in the liver is required to prevent onset of disease.  456 
We demonstrated that LSEC monocultures can maintain their unique phenotype in culture 457 
through at least 5 days of culture and were concomitantly proliferating.  Our chemically defined 458 
media system provides an in vitro platform to effectively move forward in understanding the 459 
phenomena involved in LSEC biology. 460 
 461 
 462 
463 
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FIGURE CAPTIONS 638 
Figure 1.  Lipids in FFA form sustain long-term culture.  Phase contrast images of LSEC 639 
were taken at day 5 of culture in serum-free medium (modified HGM) with regular BSA (A,B) 640 
or fatty acid (FFA)-free BSA (C,D).  LSEC were cultured with 50 ng/mL VEGF (control), plus 641 
50 μM oleic acid (50 μM OA), or 1% chemically defined lipid concentrate (1% lipid).  Only 642 
conditions with OA or lipid appeared favorable for persistence of cell culture. Higher 643 
magnification images indicate a pronounced change in morphology in lipid treated conditions 644 
compared to untreated control cells which appeared more granular (B,D). Scale bars = 50 μm 645 
(A,C), 20 μm (B,D). 646 
 647 
Figure 2.  LSEC death at 48 hours is abrogated following treatment with FFA.  Live/Dead 648 
assays were performed on LSEC culture across several conditions (A,B), with cell number 649 
quantification by Cell Profiler (C,D).  Samples were treated with calcein AM (green) for live 650 
cells and ethidium bromide homodimer (red) for dead cells.  While all conditions experienced 651 
steep drops in total population by day 3, only OA or lipid treatments had significant live cell 652 
numbers (p<5E-4 compared to control), indicating lipid type importance.  Abbreviations: PC = 653 
phosphatidylcholine, LPC = lysophosphatidylcholine, OA = oleic acid.  Scale bar = 100 μm. 654 
 655 
Figure 3.  OA and lipid supplement support phenotype and function in LSEC cultures.  656 
Alamar Blue measurements were statistically higher at days 3 (p<0.05) and 5 (p<0.005) in 50 657 
μM OA and 1% lipid supplement treatments over control for LSEC in regular BSA (A).  Similar 658 
trends were also observed in FFA free BSA cultures (B).  Alamar Blue reduction was statistically 659 
higher at day 3 for 50 μM OA and 1% lipid supplement treatments over control, PC, and LPC. At 660 
day 5, only 1% lipid supplement treatment was statistically significant over control, PC, and 661 
LPC, indicating that the 50 μM OA condition was insufficient to sustain long term cultures 662 
without the presence of other fatty acids.  Most cells in the control condition did not survive past 663 
day 3; remaining cells did not co-stain for Hoechst (blue) and Di-I-Ac-LDL (red), while OA and 664 
lipid conditions consistently co-stained for both on day 5 (C).  Contrast and brightness were 665 
adjusted for the entire image for Hoechst staining due to background fluorescence arising from 666 
the Thermanox coverslips. Abbreviations: PC = phosphatidylcholine, LPC = 667 
lysophosphatidylcholine, OA = oleic acid.  Scale bars = 100 μm (C), 2.5 μm (D).   668 
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 669 
Figure 4. Maintenance of fenestrations in FFA cultures.  LSEC cultures were evaluated for 670 
fenestrations at 3, 4 and 5 days following isolation in the presence or absence of lipid 671 
supplementation. At day 3 most cells in the control condition were dead (arrows) or had no 672 
visible fenestrations (A, D, G, J) while OA (B, E, H, K) and lipid (C, F, I, L) treated cultures 673 
displayed some cells with fenestrations arranged in sieve plates (arrowheads). Some cells 674 
displayed very large transcytotic pores (arrows). These fenestrations (arrowhead) and large pores 675 
(arrows) were maintained in a fraction of the treated cells until day 5. 676 
Magnifications: Scale bar in L represents 1 μm for panels B-F and J-L. Scale bar in I represents 677 
10 μm for panels A, G-I). 678 
 679 
Figure 5.  LSEC differentiation marker CD32b, proliferation marker PCNA, and nuclear 680 
Hoechst co-localize to same cells in FFA cultures.  5-day-old LSEC cultures were imaged for 681 
CD32b (green), nuclear PCNA antigen (red), and nuclear Hoechst dye (blue) (A).  Punctate 682 
CD32b staining was observed in the control and did not co-localize with Hoechst.  Broad, diffuse 683 
CD32b staining was observed in OA and lipid cultures on cells positive for PCNA and Hoechst, 684 
demonstrating that differentiated LSEC undergo proliferation at day 5 in vitro. Immunostaining 685 
controls for absence of CD31 (B)  and CD32b (C) signal degradation were performed. LSEC 686 
were cultured for 24 hours prior to being stained with CD31 and Hoechst (B). Samples that were 687 
permeabilized were positive for CD31 while non-permeabilized LSEC did not stain positive for 688 
CD31.  LSEC culture were highly pure in LSEC population after 24 hours using CD32b staining 689 
(C). After several days in culture, LSEC increase in surface area while CD32b staining appears 690 
to have decreased in overall intensity as compared to freshly isolated cells. This may indicate 691 
that LSEC no longer are actively synthesizing new CD32b antigen. Contrast and brightness were 692 
adjusted for the entire image due to background fluorescence arising from the Thermanox plastic 693 
coverslips.  Scale bar = 100 μm. 694 
 695 
Figure 6.  OA and lipid supplement help promote proliferation and maintain differentiation 696 
in long term LSEC culture.  Day 5 total events were captured by flow cytometry and gated for 697 
CD32b and EdU using a double negative HDMVEC (A).  Total event (cellular + debris) and 698 
cellular event counts were tallied and presented as fold number over control, showing 699 
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consistently 5-20 fold greater number of cellular events in OA and lipid conditions (B).  OA and 700 
lipid conditions maintained CD32b and were also EdU+.  LSEC with OA or lipid had statistically 701 
significant larger percentages of total events for CD32b+, EdU+, and dual CD32b+/EdU+ 702 
populations compared to control (C).  Overall CD32b expression in OA and lipid conditions 703 
were statistically significant from untreated cells (p<0.01, p<0.001).  704 
 705 
 706 
Figure 7.  Lipid and oleic acid treated LSEC had higher phospho-ERK and phospho-Akt 707 
activity.  Phospho- and total protein blots were performed for Akt and ERK at days 3 and 5 708 
(representative shown (A)).  Signaling trends observed for Akt and ERK1/2 were consistent 709 
across biological replicates.  Replicates and pixel intensity data were analyzed using ImageJ and 710 
plotted against control after normalizing to β-actin values (B).  OA and lipid conditions had 711 
higher phospho-ERK1/total phospho-ERK1 ratios than in control.  Phospho-Akt/total Akt ratios 712 
were lower in OA and lipid conditions than in control.  Total Akt increased in OA and lipid 713 
conditions (p<0.05 from control at days 3 and 5), while total ERK1 increased at day 5 (p<0.05 714 
from control). 715 
 716 
Figure 8. Oleic acid and lipid supplement support cultures through early maintenance of low 717 
threshold of phospho-Akt followed by late phosho-ERK signaling. Cells were cultured in 718 
identical conditions with PI3K inhibitor (LY294002 1 or 10 μM) or MEK1/2 inhibitor 719 
(PD0325901 0.3 or 1 μM) for 7 days. Drug inhibitors had no significant effects on cell cultures 720 
following the first day of drug inhibitor treatment (A). Significant cell integrity loss was 721 
observed in LSECs with 10 μM PI3K inhibitor, with less pronounced effects in 1 μM PI3K 722 
inhibitor by day 2, while MEK1/2 inhibitor started to affect oleic acid cultures but not 1% lipid 723 
treated SECs (B). SECs in oleic acid or 1% lipid were able to maintain culture viability by days 4 724 
and beyond in culture despite low PI3K inhibitor concentrations (C,D). MEK1/2 inhibitor did 725 
eventually affect lipid treated SECs by day 4 (C), although many cells managed to survive in low 726 
MEK1/2 inhibitor concentrations. No SECs remained by day 7 of culture with MEK1/2 inhibitor, 727 
while low PI3K inhibited SECs treated with either oleic acid or 1% lipid recovered (D). Scale 728 
bar = 100 μm. 729 
 730 
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Figure 9.  OA and lipid supplement support cultures through early maintenance of low 731 
threshold of phospho-Akt followed by late phospho-ERK signaling.  Intact cell body counts 732 
show temporal difference in Akt and ERK signaling (A-C). Low PI3K inhibitor delayed LSEC 733 
recovery in OA and lipid conditions while high concentrations prevented culture recovery as 734 
early as day 2. Following PI3K inhibition, OA condition was eventually unable to rescue the 735 
culture entirely, as the culture decline after day 5.  Delays in intact cell loss were observed for 736 
low and high MEK inhibition until day 3 in lipid conditions, and LSEC did not recover at later 737 
times following MEK inhibition.  Although control conditions contained many intact cell bodies, 738 
cells had granular morphology of dead cells observed in Figure 2.  Western blots show PI3K and 739 
MEK1/2 inhibitors effectively reduce phosphoprotein signals within the first 24 hours of 740 
treatment (D).  Abbreviations: C = Control, OA = 50 μM oleic acid, L = 1% lipid, MEKi = 741 
MEK1/2 inhibitor PD0325901, PI3Ki = PI3K inhibitor LY294002. 742 
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